BiotechTube
NeuroSolv Therapeutics

NeuroSolv Therapeutics

Cambridge, United Kingdom· Est.
neurosolvtherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3.3M

Overview

NeuroSolv Therapeutics is a clinical-stage biotech developing Perineline™, a novel small molecule therapy for spinal cord injury. The company achieved a key regulatory milestone in March 2022 with EMA Orphan Drug Designation for Perineline™, which provides a pathway for accelerated development and market authorization in major regions. NeuroSolv is now preparing to initiate a clinical trial in partnership with a leading US spinal cord trauma hospital, positioning the company to advance a potentially transformative treatment for a condition with significant unmet need.

Spinal Cord Injury

Technology Platform

Proprietary small molecule platform focused on neuro-repair and recovery for central nervous system trauma.

Funding History

2
Total raised:$3.3M
Grant$800K
Seed$2.5M

Opportunities

The global spinal cord injury market represents a multi-billion dollar unmet need with no approved disease-modifying pharmacologic therapies.
Orphan Drug Designation provides a accelerated regulatory pathway and market exclusivity in key regions.
A successful therapy could establish a new standard of care and achieve rapid adoption in trauma centers worldwide.

Risk Factors

Extreme clinical development risk as spinal cord injury is a highly challenging indication with a history of trial failures.
Financial risk as a pre-revenue, private company dependent on raising capital for expensive trials.
Competitive risk from other entities developing SCI therapies across different modalities.

Competitive Landscape

The competitive landscape for spinal cord injury includes academic research, biotech companies, and medical device firms exploring cell therapies, neuroprosthetics, rehabilitation devices, and other small molecules. NeuroSolv's differentiation lies in its specific small molecule approach and its achieved regulatory milestone (EMA ODD). It competes in a high-risk space where no product has yet achieved definitive success in restoring function.

More companies in United Kingdom →